Bacil Pharma
BACILPHARMALTD NSE
Bacil Pharma
HealthcareNSE: BACILPHARMALTD BSE: 524516 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹27.82 Cr
Volatility
Moderate
P/E Ratio
40.1
EBITDA
₹1.00 Cr
Return on Equity
6.27%
Debt to Equity
0
Book Value
₹17.55
52W High
₹61.8
52W Low
₹10.65
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.12 times its book value
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.18% over last 3 years.
Growth Rate
Revenue Growth
71.43% lower than
3Y
Net Income Growth
300% higher than
3Y
Cash Flow Change
77.5% higher than
3Y
ROE
294% higher than
3Y
ROCE
149% higher than
3Y
EBITDA Margin (Avg.)
29.87% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.03 | 0.04 | 0.05 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 | 0.03 | 0.02 | 0.07 | 0.02 |
| Operating Profit | -0.03 | -0.04 | -0.05 | -0.06 | -0.04 | -0.07 | -0.06 | -0.07 | -0.11 | -0.03 | -0.02 | -0.07 | -0.02 |
| Other Income | 0.05 | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0 | 0.09 | 1 | 0.05 | 0.06 | 0.11 | 0.09 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.49 | -0.06 | 0.02 | 0.89 | 0.02 | 0.04 | 0.04 | 0.07 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 24.72% | 0% | 0% | -1450% | 114.29% |
| Net Profit | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.48 | -0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | -0.02 |
| EPS in Rs | 0.03 | -0.02 | -0.03 | -0.07 | -0.05 | 0.81 | -0.1 | 0.01 | 0.47 | 0.01 | 0.03 | 0.43 | -0.01 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.11 | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.25 | 0.14 |
| Operating Profit | -0.11 | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.25 | -0.14 |
| Other Income | 0.08 | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.7 | 0.07 | 0.13 | 0.66 | 1.24 | 0.31 |
| Interest | 0 | 0 | 0 | 0.03 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.03 | -0.07 | 0 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.1 | -0.06 | 0.41 | 0.99 | 0.17 |
| Tax % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -57.58% | — |
| Net Profit | -0.03 | -0.07 | 0 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.1 | -0.06 | 0.4 | 1.56 | 0.65 |
| EPS in Rs | -0.05 | -0.12 | 0 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.1 | 0.28 | 1.09 | 0.46 |
| Div. Payout % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 | 13.97 |
| Reserves | -0.06 | -0.13 | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.3 | -5.43 | -5.31 | 11.46 | 10.84 |
| Borrowings | 0.14 | 0.27 | 0.31 | 0 | 0.1 | 0.17 | 0.18 | 0.03 | 0.02 | 0.1 | 0.16 | 0 |
| Other Liabilities | 0.02 | 0.02 | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 | 2.58 |
| Total Liabilities | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
| Fixed Assets | 0.01 | 5.25 | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| CWIP | 5.88 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.51 | 0.51 | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 | 24.24 |
| Other Assets | 0.23 | 0.93 | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 | 3.15 |
| Total Assets | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 | 27.39 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.26 | 0.06 | 0 | 1.44 | -0.3 | -0.38 | -0.4 | -4.01 | -0.15 | 0 | 0.4 | 0.71 |
| Investing | -0.33 | -0.05 | 0.02 | -1.2 | 0.28 | 0.39 | 0.53 | 3.81 | -0.12 | 0.08 | 0.34 | -2.38 |
| Financing | 0 | 0 | 0 | 0 | -0.16 | -0.06 | -0.07 | 0.33 | 0.06 | -0.06 | 2.08 | -0.62 |
| Net Cash Flow | -0.07 | 0.01 | 0.02 | 0.23 | -0.18 | -0.05 | 0.06 | 0.13 | -0.2 | 0.01 | 2.82 | -2.29 |
| Free Cash Flow | 0.24 | -3.21 | 0 | 1.14 | -0.3 | -0.38 | -0.4 | -4.01 | -0.15 | 0 | 0.4 | 0.71 |
| CFO/OP | -236 | -46 | 0 | -497 | 115 | 211 | 250 | 2,506 | 88 | 0 | -160 | -284 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.8% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% | 3.93% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bacil Pharma insights
49 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 22Nd May 2026
10h - Board meeting on 22 May 2026 to approve audited financial results for quarter and year ended 31 March 2026. 10h - Board meeting on 22 May 2026 to approve audited financial results for quarter and year ended 31 March 2026.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
27 Apr - Bacil Pharma reports it is not a large corporate under SEBI debt fundraising norms. 27 Apr - Bacil Pharma reports it is not a large corporate under SEBI debt fundraising norms.
3
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
27 Apr - Bacil Pharma confirms it is not a large corporate under SEBI debt fundraising framework. 27 Apr - Bacil Pharma confirms it is not a large corporate under SEBI debt fundraising framework.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
13h - Bacil Pharma reports it is not a large corporate under SEBI debt fundraising norms. 13h - Bacil Pharma reports it is not a large corporate under SEBI debt fundraising norms.
5
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
13h - Bacil Pharma confirms it is not a large corporate under SEBI debt fundraising framework. 13h - Bacil Pharma confirms it is not a large corporate under SEBI debt fundraising framework.
5
Board Meeting Intimation for Bacil Pharma Limited ("The Company") Will Be Held On 29Th August 2026 26 Aug 2026
Intimation
Frequently Asked Questions about Bacil Pharma
What does Bacil Pharma Ltd do?
Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities...
Where is Bacil Pharma Ltd (524516) listed?
Bacil Pharma Ltd trades as BACILPHARMALTD on the NSE and under code 524516 on the BSE.
Which sector does Bacil Pharma Ltd belong to?
Bacil Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bacil Pharma Ltd?
Bacil Pharma Ltd has a market capitalisation of ₹27.82 Cr, which places it in the Small Cap band.
What is the PE ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd trades at a PE ratio of 40.10, against a book value of ₹17.55 per share.
What is the 52-week high and low of Bacil Pharma Ltd?
Over the last 52 weeks Bacil Pharma Ltd has traded between ₹10.65 and ₹61.8.
What is the Return on Equity (ROE) of Bacil Pharma Ltd?
Bacil Pharma Ltd reported a return on equity of 6.27%. Its debt-to-equity ratio is 0.00.
Company Information
Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities.[1] [2]
Website bacilpharma.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524516.md for Bacil Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.